Participants may log in up to 15 minutes before the program start time on the day of the event.

Session Information
Webcast
12:00 PM - 1:00 PM ET

Speaker
Nina Shah, MD
Associate Professor of Medicine
University of California, San Francisco
Division of Hematology-Oncology
San Francisco, California

Technical Support?
For technical support, please email Meetings@ResearchToPractice.com or call (800) 233-6153. Tech support will be available starting at 11:30 AM ET on Thursday, May 28.

Agenda
Module 1 – Clinical Decision-Making for Patients with Newly Diagnosed MM
Module 2 – Contemporary Management of Relapsed/Refractory MM
Module 3 – Novel Agents in Late-Stage Development

This activity is supported by educational grants from Adaptive Biotechnologies, Celgene Corporation, GlaxoSmithKline, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, and Takeda Oncology.

Target Audience
This activity is intended for medical oncologists, hematologists and other healthcare providers involved in the treatment of MM.

Learning Objectives

• Discuss available research data informing the use of monoclonal antibody therapy directed at CD38 as a component of induction therapy for patients with MM eligible or ineligible for stem cell transplant, and effectively identify when and how this strategy should be integrated into the clinical management of this disease.
• Customize induction, consolidation and maintenance therapeutic approaches for active MM in the post-transplant and nontransplant settings, considering patient- and disease-related factors, including cytogenetic profile.
• Evaluate research data supporting a role for minimal residual disease (MRD) status in predicting long-term outcomes with therapy, and use this information to determine the potential role of MRD assays in protocol and nonresearch management of MM.
• Apply published research data and other clinical factors in the best-practice selection, sequencing or combining of available therapies in the nonresearch care of patients with relapsed/refractory MM.
• Discuss available data documenting the activity of chimeric antigen receptor T-cell therapy and antibody-drug conjugates designed to target BCMA (B-cell maturation antigen), and use this knowledge to identify patients with MM who may be appropriate for these therapeutic approaches on clinical trials.
• Assess the mechanisms of action of, available data with and ongoing clinical trials evaluating other novel, investigational approaches for MM, and consider the potential role of these therapies in clinical practice.

Physician Competencies To Be Addressed
Patient Care and Procedural Skills, Medical Knowledge.

CME Credit Form
To receive credit for this program, you may complete an evaluation for AMA PRA credits and receive your CME certificate. A link will be available here within an hour of the meeting.

Contact Information
For questions regarding credit, please contact USF Health at cpdsupport@usf.edu or 813-224-7860.

Accreditation Statement
USF Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

USF Health designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclaimer
The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.

Equal Opportunity Statement
USF Health is an Equal Opportunity/Affirmative Action/Equal Access Institution.

Disclosure Policy
USF Health adheres to ACCME Standards regarding commercial support of continuing medical education. It is the policy of USF Health and Research To Practice that the faculty and planning committee disclose real or apparent conflicts of interest relating to the topics of this educational activity, that relevant conflict(s) of interest are resolved and also that speakers will disclose any unlabeled/unapproved use of drug(s) or device(s) during their presentation.

STEERING COMMITTEE — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Rafael Fonseca, MD
Getz Family Professor of Cancer
Director for Innovation and Transformational Relationships
Interim Executive Director of the Mayo Clinic Comprehensive Cancer Center
Chair, Department of Internal Medicine
Distinguished Mayo Investigator
Mayo Clinic in Arizona
Phoenix, Arizona

Advisory Committee: Adaptive Biotechnologies; Consulting Agreements: AbbVie Inc, Amgen Inc, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, Janssen Biotech Inc, Kite, A Gilead Company, Merck, Novartis, Sanofi Genzyme, Takeda Oncology.

Shaji K Kumar, MD
Professor of Medicine
Consultant
Division of Hematology and Blood and Marrow Transplantation
Mayo Clinic
Rochester, Minnesota

Consulting Agreements: AbbVie Inc, Adaptive Biotechnologies, Amgen Inc, AstraZeneca Pharmaceuticals LP, Celgene Corporation, GeneCentrix Inc, Genentech, a member of the Roche Group, Janssen Biotech Inc, Kite, A Gilead Company, Merck, Molecular Partners, Oncopeptides, Takeda Oncology; Contracted Research: AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Carson, Celgene Corporation, Genentech, a member of the Roche Group, Janssen Biotech Inc, Kite, A Gilead Company, Merck, Novartis, Roche Laboratories Inc, Sanofi Genzyme, Takeda Oncology, TeneoBio; Data and Safety Monitoring Board/Committee: Sanofi Genzyme.

Ola Landgren, MD, PhD
Professor of Medicine
Chief, Myeloma Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Consulting Agreements and Speakers Bureau: Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, Janssen Biotech Inc; Contracted Research: Amgen Inc, Janssen Biotech Inc, Takeda Oncology; Data and Safety Monitoring Board/Committee: Janssen Biotech Inc, Merck, Takeda Oncology, Theradex Oncology.

Sagar Lonial, MD
Chair and Professor
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Consulting Agreements: Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, GlaxoSmithKline, Janssen Biotech Inc, Novartis, Takeda Oncology; Contracted Research: Celgene Corporation, Janssen Biotech Inc, Takeda Oncology.

Nikhil C Munshi, MD
Professor of Medicine, Harvard Medical School
Director of Basic and Correlative Science
Associate Director, Jerome Lipper Multiple Myeloma Center
Department of Medical Oncology
Dana-Farber Cancer Institute
Boston, Massachusetts

Consulting Agreements: AbbVie Inc, Adaptive Biotechnologies, Amgen Inc, BeiGene, Celgene Corporation, Janssen Biotech Inc, Karyopharm Therapeutics, OncoPep, Takeda Oncology; Ownership Interest: OncoPep.

Robert Z Orlowski, MD, PhD
Florence Maude Thomas Cancer Research Professor
Department of Lymphoma and Myeloma
Professor, Department of Experimental Therapeutics
Director, Myeloma Section
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas

Advisory Committee: Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, EcoR1 Capital LLC, FORMA Therapeutics, Genzyme Corporation, GlaxoSmithKline, Ionis Pharmaceuticals Inc, Janssen Biotech Inc, Juno Therapeutics, a Celgene Company, Kite, A Gilead Company, Legend Biotech, Molecular Partners, Sanofi Genzyme, Servier, Takeda Pharmaceuticals North America Inc; Contracted Research: BioTheryX Inc.

Noopur Raje, MD
Director, Center for Multiple Myeloma
Massachusetts General Hospital Cancer Center
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Consulting Agreements: Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, Novartis, Onyx Pharmaceuticals, an Amgen subsidiary, Takeda Oncology; Contracted Research: AstraZeneca Pharmaceuticals LP, Lilly.

Nina Shah, MD
Associate Professor of Medicine
University of California, San Francisco
Division of Hematology-Oncology
San Francisco, California

Consulting Agreements: Amgen Inc, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, GlaxoSmithKline, Indapta Therapeutics, Karyopharm Therapeutics, Nektar, Oncopeptides, Precision BioSciences, Sanofi Genzyme, Seattle Genetics, Surface Oncology; Ownership Interest: Indapta Therapeutics; Contracted Research: bluebird bio, Celgene Corporation, Janssen Biotech Inc, Sutro Biopharma, TeneoBio.

PROJECT CHAIR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Tolero Pharmaceuticals.

USF HEALTH CPD STAFF, RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — No relevant conflicts of interest to disclose.